>75%

Most men with an elevated PSA will have a prostate biopsy negative for clinically significant cancer.

The Challenge

You strive to provide an accurate, stress-free, and appropriate care experience for your patients. Yet, current prostate cancer screening practices are inconclusive. Over 75% of men with an elevated PSA do not have clinically significant cancer and do not need additional invasive, costly, and risky testing.

95%

NPV for Biopsy
Naïve Men

99%
95%
99%

NPV for Biopsy
Naïve Men

NPV for Men with
Prior Negative Biopsy

The Solution

MyProstateScore 2.0 (MPS2) is a non invasive, genetically data-driven prostate cancer screening solution that provides highly accurate, stratified risk assessment insights to guide clinical decisions and improve your patients’ experience.

Transformational Accuracy

Prostate Cancer Risk Screening Lab Technician

Personalized Risk.
Stratified Insights.

MPS2 improves on the foundational technology of MPS, a test included in the National Comprehensive Cancer Network® (NCCN®) guidelines related to prostate cancer diagnosis.

The MPS2 algorithm has been developed to optimize accuracy. For biopsy naïve patients, MPS2 is a standalone biomarker test.

For patients with a prior negative biopsy, clinical factors most relevant to repeat biopsy patients have been included in the algorithm. These patients present a unique clinical challenge. We offer proven performance data for this population.1

The specificity of the T2:ERG fusion gene, the foundation of MPS2, with a supporting array of 17 other genetic biomarkers that characterize prostate cancer, offers population-specific results with next generation accuracy.

Proven Performance for Biopsy Naïve Patients

In men who have never had a prostate biopsy, a low risk result identifies...
1/3 of those patients would receive a negative biopsy result.

Unrivaled Accuracy for Prior Negative Biopsy Patients

In men being considered for a repeat biopsy, a low risk result identifies...
1/2 of those men would receive a negative biopsy result.

How MPS2 Is Different

Testing for the Most Specific Prostate Cancer Biomarkers Available

Different populations and each individual have specific genetic histories and necessary clinical paths. That’s why MPS2 is built on a cohort-specific algorithm to optimize diagnostic accuracy and provide clinical flexibility for biopsy naïve patients and patients with a prior negative biopsy.

MPS2 provides the stratified insights you need to continue to guide your patient on the best treatment path.

18 Unique Gene Transcripts

Using a simple post-DRE urine sample, MPS2 analyzes 18 unique gene transcripts shown to predict clinically significant cancer. Among these, the test’s foundation is the novel gene fusion T2:ERG.

T2:ERG is present in most men with prostate cancer and is the most specific prostate cancer biomarker available.

Next-Generation Accuracy and Simplicity

Enhanced diagnostics is as easy as a 30-second urine sample. We do the analysis. You gain greater and personalized insights to guide your patient.

Clear Results. Improved Insights. No Surprises.

We are committed to best-in-class diagnostic testing services to help people live healthy and productive lives. We offer you and your patients simplicity and a stress-free experience.

Urine Sample icon

Simple Post-DRE Urine Test

See How It Works →

Report icon

Clear, Comprehensive Results

Mitigated Reimbursement Concerns

Clinical Publications and Research

Expert Validation of Precision Molecular Diagnostics

MPS2 and its foundational T2:ERG gene fusion are rooted in award-winning research at the University of Michigan, developed and validated in conjunction with the National Institute of Health’s Early Detection Research Network, and supported by a growing body of peer-reviewed literature.

1Adapted from “Development and Validation of MyProstateScore 2.0 to Detect Clinically Significant Prostate Cancer,” by Tosoian, et al., 2023, medRxiv, (https://doi.org/10.1101/2023.04.11.23288418)